Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Theranovis Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is assigned to 1 examiner and 1 art unit, producing a single examination path.
GIERE, REBECCA M is the busiest examiner, with 1 pending matter. Counsel can direct technical and claim analysis toward that examiner’s treatment of the biotechnology and pharmaceutical subject matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GIERE, REBECCA M | 1 | 73.8% | +32.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557802 | METHOD FOR PROVIDING INFORMATION FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITOR IN CANCER PATIENT USING MULTIPLE IMMUNOHISTOCHEMICAL STAINING | GIERE, REBECCA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18557802 | METHOD FOR PROVIDING INFORMATION FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITOR IN CANCER PATIENT USING MULTIPLE IMMUNOHISTOCHEMICAL STAINING | GIERE, REBECCA M | — |
| Art Unit | Apps |
|---|---|
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18557802 | METHOD FOR PROVIDING INFORMATION FOR PREDICTING THERAPEUTIC RESPONSIVENESS TO IMMUNE CHECKPOINT INHIBITOR IN CANCER PATIENT USING MULTIPLE IMMUNOHISTOCHEMICAL STAINING | GIERE, REBECCA M | 1677 | §101 | Final Rejection | — | Pending | Oct 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTheranovis Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Rebecca M Giere has the most, with 1 of Theranovis Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.